{"filing":{"accession_number":"0001654954-26-008478","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"a4455v.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008478/a4455v.htm"},"events":[{"id":33856,"run_id":31159,"accession_number":"0001654954-26-008478","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This disclosure announces a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for EU approval of Klygefa (gefurulimab) for treating generalised myasthenia gravis. The announcement details successful Phase III trial results (PREVAIL) meeting primary endpoints and describes the drug's mechanism and market opportunity. This is a material regulatory milestone for a rare disease therapeutic that, if approved, would be the first dual-binding nanobody C5 inhibitor in the EU for this indication—a significant operational and commercial achievement for AstraZeneca's Alexion subsidiary, though not a discrete event type like M\u0026A, earnings, or executive change.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-21","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":37417,"accession_number":"0001654954-26-008478","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for EU approval of Klygefa (gefurulimab) for treating generalised myasthenia gravis. The announcement details successful Phase III trial results (PREVAIL) meeting primary endpoints and describes the drug's mechanism and market opportunity. This is a material regulatory milestone for a rare disease therapeutic that, if approved, would be the first dual-binding nanobody C5 inhibitor in the EU for this indication—a significant operational and commercial achievement for AstraZeneca's Alexion subsidiary, though not a discrete event type like M\u0026A, earnings, or executive change.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:05:37.017307+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-21"}]}